Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon secretion. GLP-1 derivatives possess promising therapeutic outcomes in treating typ